247 related articles for article (PubMed ID: 17038330)
1. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins.
Jónsson SR; Haché G; Stenglein MD; Fahrenkrug SC; Andrésdóttir V; Harris RS
Nucleic Acids Res; 2006; 34(19):5683-94. PubMed ID: 17038330
[TBL] [Abstract][Full Text] [Related]
2. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.
Haché G; Liddament MT; Harris RS
J Biol Chem; 2005 Mar; 280(12):10920-4. PubMed ID: 15647250
[TBL] [Abstract][Full Text] [Related]
3. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
Langlois MA; Beale RC; Conticello SG; Neuberger MS
Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
[TBL] [Abstract][Full Text] [Related]
4. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals.
LaRue RS; Jónsson SR; Silverstein KA; Lajoie M; Bertrand D; El-Mabrouk N; Hötzel I; Andrésdóttir V; Smith TP; Harris RS
BMC Mol Biol; 2008 Nov; 9():104. PubMed ID: 19017397
[TBL] [Abstract][Full Text] [Related]
5. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
Albin JS; Brown WL; Harris RS
Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.
Siu KK; Sultana A; Azimi FC; Lee JE
Nat Commun; 2013; 4():2593. PubMed ID: 24185281
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain.
Bohn MF; Shandilya SM; Albin JS; Kouno T; Anderson BD; McDougle RM; Carpenter MA; Rathore A; Evans L; Davis AN; Zhang J; Lu Y; Somasundaran M; Matsuo H; Harris RS; Schiffer CA
Structure; 2013 Jun; 21(6):1042-50. PubMed ID: 23685212
[TBL] [Abstract][Full Text] [Related]
9. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
Liddament MT; Brown WL; Schumacher AJ; Harris RS
Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
[TBL] [Abstract][Full Text] [Related]
10. [Mechanisms for inhibition of retrovirus replication by APOBEC3 family].
Iwatani Y
Uirusu; 2011 Jun; 61(1):67-72. PubMed ID: 21972557
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3F Constitutes a Barrier to Successful Cross-Species Transmission of Simian Immunodeficiency Virus SIVsmm to Humans.
Nchioua R; Kmiec D; Gaba A; Stürzel CM; Follack T; Patrick S; Kirmaier A; Johnson WE; Hahn BH; Chelico L; Kirchhoff F
J Virol; 2021 Aug; 95(17):e0080821. PubMed ID: 34132575
[TBL] [Abstract][Full Text] [Related]
12. Influence of the DNA sequence/length and pH on deaminase activity, as well as the roles of the amino acid residues around the catalytic center of APOBEC3F.
Wan L; Nagata T; Katahira M
Phys Chem Chem Phys; 2018 Jan; 20(5):3109-3117. PubMed ID: 28825755
[TBL] [Abstract][Full Text] [Related]
13. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
[TBL] [Abstract][Full Text] [Related]
14. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.
Hultquist JF; Lengyel JA; Refsland EW; LaRue RS; Lackey L; Brown WL; Harris RS
J Virol; 2011 Nov; 85(21):11220-34. PubMed ID: 21835787
[TBL] [Abstract][Full Text] [Related]
15. The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.
Richards C; Albin JS; Demir Ö; Shaban NM; Luengas EM; Land AM; Anderson BD; Holten JR; Anderson JS; Harki DA; Amaro RE; Harris RS
Cell Rep; 2015 Dec; 13(9):1781-8. PubMed ID: 26628363
[TBL] [Abstract][Full Text] [Related]
16. Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance.
Haché G; Mansky LM; Harris RS
AIDS Rev; 2006; 8(3):148-57. PubMed ID: 17078485
[TBL] [Abstract][Full Text] [Related]
17. A novel HIV-1 restriction factor that is biologically distinct from APOBEC3 cytidine deaminases in a human T cell line CEM.NKR.
Zhou T; Han Y; Dang Y; Wang X; Zheng YH
Retrovirology; 2009 Apr; 6():31. PubMed ID: 19344514
[TBL] [Abstract][Full Text] [Related]
18. Retroviral restriction by APOBEC proteins.
Harris RS; Liddament MT
Nat Rev Immunol; 2004 Nov; 4(11):868-77. PubMed ID: 15516966
[TBL] [Abstract][Full Text] [Related]
19. APOBEC3F determinants of HIV-1 Vif sensitivity.
Land AM; Shaban NM; Evans L; Hultquist JF; Albin JS; Harris RS
J Virol; 2014 Nov; 88(21):12923-7. PubMed ID: 25142588
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3 Host Restriction Factors of HIV-1 Can Change the Template Switching Frequency of Reverse Transcriptase.
Adolph MB; Ara A; Chelico L
J Mol Biol; 2019 Mar; 431(7):1339-1352. PubMed ID: 30797859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
